AI drug discovery must deliver repeatable value beyond hype: Insilico Medicine's Feng Ren

AI-driven drug discovery is enhancing early-stage target identification and molecule design by significantly reducing development timelines and costs, with some AI-discovered candidates advancing into late-stage clinical trials. The lasting value depends on integrating AI with human expertise to produce reproducible scientific results and validated clinical outcomes, separating credible platforms from hype.

This Wire brief sits within Fusion42's coverage of Drug Discovery.